Arcadia Biosciences, Inc. 10-Q

ITEM 5. OTHER INFORMATION None. 27 ITEM 6. E XHIBITS The following exhibits are attached hereto or are incorporated herein by reference. Exhibit Number Exhibit Description 10.1(1) Employment letter for Stanley E. Jacot, Jr., Chief Executive Officer 10.2(1)(2) Inducement Option Grant for Stanley E. Jacot, Jr. 10.3(1)(3) Severance and Change in Control Agreement for Stanley E. Jacot, Jr. 31.1 Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Principal Financial Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1(4) Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2(4) Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104.1 Cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in inline XBRL (and contained in Exhibit 101) (1) Indicates a management contract or compensatory plan, contract or arrangement in which any Director or any Executive Officer participates. (2) Incorporated by reference to Exhibit 10.2 filed with the Report on Form 8-K filed on February 7, 2022. (3) Incorporated by reference to Exhibit 10.1 filed with the Report on Form 8-K filed on February 7, 2022. (4) This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. 28 SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Arcadia Biosciences, Inc. May 12, 2022 By: /s/ STANLEY E. JACOT, JR. Stanley E. Jacot, Jr. President and Chief Executive Officer May 12, 2022 By: /s/ PAMELA HALEY Pamela Haley Chief Financial Officer 29